Medical college

BostonGene and the Medical College of Wisconsin Announce the Publication and Journal Cover Feature in Gastroenterology Highlighting Transcriptomic-Based Tumor Microenvironment Classification for Precision Medicine in Pancreatic Cancer

Retrieved on: 
Montag, Mai 6, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, University, Science, Education, Oncology, Cancer, Pancreas, Pancreatic cancer, MCW, Prognosis, Immunotherapy, Tumor microenvironment, Intelligence, Disease, Liver, Patient, Human, Fibrosis, Gene expression, Multimedia, Manuscript, Immune system, Medical director, Medical college, Gastrointestinal disease, TME, Pharmaceutical industry

BostonGene’s artwork was also chosen for the cover of the May publication.

Key Points: 
  • BostonGene’s artwork was also chosen for the cover of the May publication.
  • The journal highlights original research, reviews and expert insights in adult and pediatric gastroenterology and hepatology, covering clinical, translational and basic aspects of the digestive system, liver, pancreas and nutrition.
  • The study identified four distinct tumor microenvironment (TME) subtypes, unveiling a promising path forward in the fight against PDAC and underscoring the importance of considering TME features in personalized therapeutic strategies.
  • “For a long while, the scientific community believed that pancreatic cancer was not responsive to immunotherapy, which uses a person’s own immune system to fight cancer.

Medical College of Wisconsin Cancer Center leads groundbreaking change in Medicare policy for MDS patients over 65 in need of lifesaving transplants

Retrieved on: 
Mittwoch, Mai 8, 2024
BMT, NMDP, Transplant, MCW, National Marrow Donor Program, MD, HCT, Research, Doctor of Science, History, Syndrome, ASH, Patient, Society, Medicare, Blood, MDS, Cancer, Medical college

MDS is a group of cancers that affect the body's ability to produce healthy blood cells.

Key Points: 
  • MDS is a group of cancers that affect the body's ability to produce healthy blood cells.
  • Allogeneic HCT is the only curative therapy for patients with MDS.
  • This challenge was further exacerbated since older adults were, consequently, overlooked as candidates for transplant because they did not have Medicare coverage for the procedure.
  • A final decision was recently made by Medicare in the form of a National Coverage Analysis Decision Memo to expand Medicare coverage for the affected population.

The Inner Circle Acknowledges, Randi Leigh Sessoms Lassiter as a Distinguished Healthcare Provider

Retrieved on: 
Montag, Mai 6, 2024
APSA, Hospital, American Pediatric Surgical Association, Travel, Trauma, Love, Research, Parent, Photography, Disease, Duke University, ACS, Patient, Bachelor, College, Multimedia, Philosophy, Inner circle, Medical college, Medical degree, Nursing

MINNEAPOLIS, May 6, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Randi Leigh Sessoms Lassiter is acknowledged as a Distinguished Healthcare Provider for her contributions to the field of Pediatric Surgery.

Key Points: 
  • MINNEAPOLIS, May 6, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Randi Leigh Sessoms Lassiter is acknowledged as a Distinguished Healthcare Provider for her contributions to the field of Pediatric Surgery.
  • Dr. Lassiter prepared for her vocation attending the College of William and Mary where she earned a Bachelor's degree.
  • She then attended Duke University and received a Medical Degree; completed a residency at the Medical College of Georgia; and a fellowship at Nicholas Children's Hospital.
  • Dr. Lassiter has many highlights in her career and considers becoming board certified in 2023 and finishing her fellowship as her greatest career accomplishment.

The Inner Circle Acknowledges, Divyakant B. Gandhi, MBBS, FRCS, FACS, Circle as a Distinguished Cardiothoracic Surgeon

Retrieved on: 
Montag, Mai 6, 2024
Doctor of Philosophy, Education, Atrial fibrillation, Cardiothoracic surgery, American College, Multimedia, Lung cancer, MBBS, Coronary artery disease, Mentorship, Ohio State University, Ventricular septal defect, Elective surgery, Heart, Parent, Research, University, FACS, Multiple, Lung, Inner circle, McLaren Health Care Corporation, Patient, Medicine, Circulatory system, Physician, Intellectual property, Health, Mitral valve, FRCS, Student, General surgery, Quality of life, Georgia Tech, Medical college, Royal, Royal college

Divyakant B. Gandhi is an international physician, innovative thinker, and leader in cardiac care.

Key Points: 
  • Divyakant B. Gandhi is an international physician, innovative thinker, and leader in cardiac care.
  • He has been in practice as a Heart, Lung & Vascular surgeon for over 35 years.
  • As a leader in the clinical setting, Dr. Gandhi is the Chief of Staff, Medical Director, and Chief of Cardiovascular & Thoracic Surgery at McLaren Greater Lansing.
  • Dr. Gandhi practices his specialty under the auspices of the Center for Cardiovascular and Thoracic Surgery in Detroit, MI.

Dr. Ahmed Z. Obeidat Named Finalist for the 2024 "CMSC Neuroinnovator of the Year"

Retrieved on: 
Montag, Mai 6, 2024
Dementia, Prevalence, Dermatology, Cognition, Thought, Research, Light, Background, Patient, Fatigue, Psoriasis, Biomarker, Light therapy, Walking, CMSC, Medical college, Pharmaceutical industry

"This trial targets the biggest unmet need in MS, which is fatigue and the cognitive difficulties associated with it. The trial will be able to detect changes in improved fatigue, stabilization, and maybe even improve cognition," said Dr. Obeidat. "I think the inclusive target patient population within the Silent Symptoms trial will change our thinking about who should be enrolled in clinical trials. Most trials have been very selective -- excluding people who are not walking, or are over age 60, and so on. The Silent Symptoms trial will go all in, taking any MS patient with fatigue, which is the vast majority of our patients, and offering them phototherapy lights that they can take home."

Key Points: 
  • The recognition highlights the groundbreaking work and innovative approach sponsored by Cytokind, Inc. in addressing unmet needs in MS treatment.
  • The trial will be able to detect changes in improved fatigue, stabilization, and maybe even improve cognition," said Dr. Obeidat.
  • The 2024 CMSC Neuroinnovation Competition aims to recognize and celebrate original and innovative work in the field of MS research.
  • The finalists will present their ideas at the annual CMSC conference in Nashville, Tennessee, from May 29 to June 1.

Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer

Retrieved on: 
Donnerstag, Mai 2, 2024
University, Cancer, Johns Hopkins Hospital, IND, Genetics, Johns Hopkins, Pancreas, Thomas Jefferson University, Patient, Macrophage, CARM, Louisiana State University, Associate, Therapy, Lumos, Medical college

PHILADELPHIA, May 2, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Eugene P. Kennedy, M.D., F.A.C.S. as the Company's Chief Medical Officer. Dr. Kennedy brings over 15 years of clinical and industry experience, including cross-functional leadership driving clinical development and regulatory strategies for oncology and immuno-oncology focused organizations. In the role of Chief Medical Officer, Dr. Kennedy will be responsible for overseeing Carisma's clinical development, regulatory and medical affairs functions.

Key Points: 
  • In the role of Chief Medical Officer, Dr. Kennedy will be responsible for overseeing Carisma's clinical development, regulatory and medical affairs functions.
  • "On behalf of Carisma, I am delighted to welcome Gene to our team," said Steven Kelly, President and Chief Executive Officer of Carisma.
  • Before joining Carisma, Dr. Kennedy served as Chief Medical Officer at Galera Therapeutics, where he oversaw the development of the company's radiotherapy in cancer.
  • Before Lumos, Dr. Kennedy held the role of Chief Medical Officer at NewLink Genetics, overseeing clinical trials across multiple product candidates and indications.

The Inner Circle Acknowledges Aaron T. Scott, DHA, CNMT, NMAA, FSNMMI-TS as a Distinguished Professional

Retrieved on: 
Montag, April 29, 2024
Health administration, Capella University, Professional, Nuclear medicine, DHA, Health, Publication, Spectrum, Teaching, Clark Atlanta University, Molecular biophysics, Health care, Johns Hopkins Hospital, GLEN, IRB, ACLS, Inner circle, BLS, Master, NMAA, Multimedia, Mediocre, Doctorate, Medical college, Nursing

GLEN BURNIE, Md., April 29, 2024 /PRNewswire/ -- Aaron T. Scott, DHA, CNMT, NMAA, FSNMMI-TS is being recognized by The Inner Circle as a Distinguished Professional for his work in healthcare.

Key Points: 
  • GLEN BURNIE, Md., April 29, 2024 /PRNewswire/ -- Aaron T. Scott, DHA, CNMT, NMAA, FSNMMI-TS is being recognized by The Inner Circle as a Distinguished Professional for his work in healthcare.
  • As Vice President of Clinical Operations, Aaron holds a pivotal role at the Advanced Molecular Imaging & Therapy in Glen Burnie, MD.
  • Aaron ensures that clinical operations knowledge is effectively integrated into various clinical development activities.
  • He has held leadership positions in professional organizations, received awards, and made significant contributions to the field through publications and educational speaking engagements.

NMDP to Present New Stem Cell Transplantation Data at the 2024 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Mittwoch, April 24, 2024
City, NMDP, MMUD, HLA, Haematopoietic system, Hematology, Hope, HCT, Research, Associate professor, ASCO, Bone marrow, Patient, ACCESS, Society, CDT, Medical college, Dentistry

MINNEAPOLIS, April 24, 2024 (GLOBE NEWSWIRE) -- NMDP℠, a global nonprofit leader in cell therapy, and CIBMTR® (Center for International Blood and Marrow Transplant Research®) will present new data on hematopoietic cell transplantation (HCT) treatment effects in patients with hematological malignancies at the American Society of Clinical Oncology (ASCO) Annual Meeting May 31–June 4, 2024, in Chicago, Ill., and online.

Key Points: 
  • MINNEAPOLIS, April 24, 2024 (GLOBE NEWSWIRE) -- NMDP℠, a global nonprofit leader in cell therapy, and CIBMTR® (Center for International Blood and Marrow Transplant Research®) will present new data on hematopoietic cell transplantation (HCT) treatment effects in patients with hematological malignancies at the American Society of Clinical Oncology (ASCO) Annual Meeting May 31–June 4, 2024, in Chicago, Ill., and online.
  • A chief focus will be sharing interim findings from ACCESS, the prospective, multi-center, Phase II clinical trial of HCT using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children.
  • “New findings from the ACCESS study will advance broader understanding of how mismatched unrelated donors can safely and effectively address gaps in equitable access to transplant for those patients who are unable to find a fully matched donor,” said Steven M. Devine, M.D., Chief Medical Officer, NMDP; Senior Scientific Director, CIBMTR.
  • Presenting Author: Monzr M. Al Malki, M.D., Associate Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
    Title: Identifying states for targeted alloHCT access initiatives using social vulnerability, physician density, and unmet need
    Full abstracts will be available at 4 p.m. CDT, May 23, 2024, on the ASCO Annual Meeting website .

Stephens Announces New Leadership Within Institutional Equities & Research Group

Retrieved on: 
Montag, April 29, 2024
Professional Services, Finance, Neuropsychology, Research, Media, CIBC World Markets, Advertising, CIBC, Medical college, Hatmaking

Stephens, an independent financial services firm, today announced Joe Dacus is the new Head of Sales and James Law is the new Head of Trading of Stephens Institutional Equities practice effective immediately.

Key Points: 
  • Stephens, an independent financial services firm, today announced Joe Dacus is the new Head of Sales and James Law is the new Head of Trading of Stephens Institutional Equities practice effective immediately.
  • They join Director of Research Kyle Evans, in shared leadership of Stephens Institutional Equities practice.
  • Mr. Evans, based in Little Rock, has been with Stephens for more than 25 years and has been Director of Research since 2021.
  • Stephens Institutional Equities and Research group provides clients proprietary research, superb execution, and deep industry knowledge.

BYG4lab®, Innovator of Next Generation Software Suites for Laboratories and Diagnostics, Appoints Tim Bickley as VP Sales US to Spearhead Entry into US market

Retrieved on: 
Mittwoch, April 10, 2024
Averett University, Society, ASM, Infection, Laboratory, Epidemiology, ASCP, MLS, Medical laboratory scientist, LIS, Health technology, Diagnosis, HIMSS, Patient, Microbiology, Data management, EWC, Health, MBA, Health information management, Medical college, IVD, Medical device

This key executive appointment and expansion marks a significant milestone to introduce the company’s innovative laboratory solutions to the US.

Key Points: 
  • This key executive appointment and expansion marks a significant milestone to introduce the company’s innovative laboratory solutions to the US.
  • BYG4lab is a global software company specializing in clinical laboratory and diagnostic data management solutions.
  • Prior to joining BYG4lab, Tim held VP Sales and Marketing roles at leading laboratory information solution vendors.
  • ASM - American Society for Microbiology, June 13th - 17th, Atlanta, GA.
    ADLM - Association for Diagnostics & Laboratory Management, July 28 - August 1st, Chicago, IL.